期刊论文详细信息
Immunity & Ageing
Seropositivity for CMV and IL-6 levels are associated with grip strength and muscle size in the elderly
John M Starr4  Ian J Deary5  Joanna M Wardlaw2  Mark E Bastin2  Paul Moss3  Rowan Harrison4  Charlotte Firth3  Alixe HM Kilgour1 
[1] Clinical Research Imaging Centre, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK;Brain Research Imaging Centre, Division of Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK;School for Cancer Sciences, University of Birmingham, Birmingham B15 2TT, UK;Geriatric Medicine Unit, University of Edinburgh, Edinburgh, UK;Department of Psychology, University of Edinburgh, Edinburgh, UK
关键词: Immunosenescence;    Interleukin-6;    Cytomegalovirus;    Grip strength;    Sarcopenia;   
Others  :  814889
DOI  :  10.1186/1742-4933-10-33
 received in 2012-12-05, accepted in 2013-08-12,  发布年份 2013
PDF
【 摘 要 】

Background

Sarcopenia is an important cause of morbidity and mortality in older adults, with immunosenescence and inflammation being possible underlying mechanisms. We investigated the relationship between latent cytomegalovirus (CMV) infection, Interleukin 6 (IL-6) levels, muscle size and strength in a group of healthy older community-dwelling people.

Methods

Participants were healthy volunteers from the Lothian Birth Cohort 1936 study. Participants had IL-6 level and CMV antibody titre measured at age 70 years and grip strength and a volumetric T1-weighted MRI brain scan (allowing measurement of neck muscle cross-sectional area (CSA)) at age 73. Markers of childhood deprivation were adjusted for in the analysis due to correlations between childhood deprivation and latent CMV infection.

Results

866 participants were studied; 448 men (mean age 72.48 years, sd 0.70) and 418 women (mean age 72.51 years, sd 0.72). In men, CMV seropositivity was associated with smaller neck muscle CSA (p = 0.03, partial eta squared = 0.01), even after adjustment for IL-6 levels. Neck muscle CSA was not associated with CMV seropositivity in women, or CMV antibody titre or IL-6 level in either sex. Grip strength associated negatively with IL-6 level (right grip strength p<0.00001, partial eta squared 0.032 and left grip strength p<0.00001, partial eta squared 0.027) with or without adjustment for CMV serostatus or antibody titre. CMV status and antibody titre were not significantly associated with grip strength in either hand.

Conclusion

These findings support the hypothesis that there is a relationship between markers of immunosenescence (i.e. CMV serostatus and IL6 level) and low muscle mass and strength and longitudinal studies in older cohorts are now required to investigate these relationships further.

【 授权许可】

   
2013 Kilgour et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140710051148888.pdf 208KB PDF download
【 参考文献 】
  • [1]Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Van-dewoude M, Zamboni M: Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010, 39:412-423.
  • [2]Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De-Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M, Sarcopenia : An undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011, 12:249-256.
  • [3]Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Fanelli FR, Schneider SM, Schols A, Sieber CC: Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by special interest groups (sig) “Cachexia-anorexia in chronic wasting diseases” and “Nutrition in geriatrics”. Clin Nutr 2010, 29:154-159.
  • [4]Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di-Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L: Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003, 95:1851-1860.
  • [5]Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998, 147:755-763.
  • [6]Rantanen T: Muscle strength, disability and mortality. Scand J Med Sci Sports 2003, 13:3-8.
  • [7]Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB, Hlth ABCS: The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol Biol Sci & Med Sci 2006, 61:1059-1064.
  • [8]Visser M, Deeg DJH, Lips P: Low vitamin d and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol Metab 2003, 88:5766-5772.
  • [9]Pawelec G, Akbar A, Beverley P, Caruso C, Derhovanessian E, Fülöp T, Griffiths P, Grubeck-Loebenstein B, Hamprecht K, Jahn G, Kern F, Koch SD, Larbi A, Maier AB, Macallan D, Moss P, Samson S, Strindhall J, Trannoy E, Wills M: Immunosenescence and cytomegalovirus: where do we stand after a decade? Immunity & Ageing 2010, 7:13. BioMed Central Full Text
  • [10]Lubeck PR, Doerr HW, Rabenau HF: Epidemiology of human cytomegalovirus (hcmv) in an urban region of Germany: what has changed? Med Microbiol Immunol 2010, 199:53-60.
  • [11]Lopo S, Vinagre E, Palminha P, Paixao MT, Nogueira P, Freitas MG: Seroprevalence to cytomegalovirus in the Portuguese population, 2002–2003. Euro Surveill 2011, 16:19896.
  • [12]Soderberg-Naucler C, Nelson JY: Human cytomegalovirus latency and reactivation - a delicate balance between the virus and its host’s immune system. Intervirology 1999, 42:314-321.
  • [13]Sinclair J: Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 2008, 41:180-185.
  • [14]Slobedman B, Cao JZ, Avdic S, Webster B, McAllery S, Cheung AK, Tan JC, Abendroth A: Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiol 2010, 5:883-900.
  • [15]Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G, Ossendorf M, Steinhagen K, Meyer J, Group ftA: Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 2001, 103:2915-2921.
  • [16]Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL: Cytomegalovirus seropositivity and c-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000, 102:1917-1923.
  • [17]Strandberg TE, Pitkala KH, Tilvis RS: Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. Jama 2009, 301:380-382.
  • [18]Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W: The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc 2006, 54:1046-1054.
  • [19]Roberts ET, Haan MN, Dowd JB, Aiello AE: Cytomegalovirus antibody levels, inflammation, and mortality among elderly latinos over 9 years of follow-up. Am J Epidemiol 2010, 172:363-371.
  • [20]Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD: Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc 2005, 53:747-754.
  • [21]Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA: Cardiovascular Health study C: frailty in older adults: evidence for a phenotype. J Gerontol Sci & Med Sci 2001, 56:M146-M156.
  • [22]Rockwood K, Mitnitski A: Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007, 62:722-727.
  • [23]Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
  • [24]Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J: Interleukin-6 and selected plasma-proteins in healthy-persons of different ages. Neurobiol Aging 1994, 15:771-772.
  • [25]Ershler WB, Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000, 51:245-270.
  • [26]Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB: Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health Abc study. J Gerontol Sci & Med Sci 2002, 57:M326-M332.
  • [27]Schaap LA, Pluijm SMF, Deeg DJH, Visser M: Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006, 119:e9-e17.
  • [28]Geist LJ, Dai LY: Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 1996, 62:653-658.
  • [29]Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, McDyer JF, Semba RD, Casolaro V, Walston JD, Fried LP: Cytomegalovirus infection and the risk of mortality and frailty in older women: A prospective observational cohort study. Am J Epidemiol 2010, 171:1144-1152.
  • [30]Cohen J: Statistical power analysis for the behavioral sciences, ed Second edition. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.
  • [31]Young A, Stokes M, Crowe M: The size and strength of the quadriceps muscles of old and young men. Clin Physiol 1985, 5:145-154.
  • [32]Skelton DA, Greig CA, Davies JM, Young A: Strength, power and related functional ability of healthy people aged 65–89 years. Age Ageing 1994, 23:371-377.
  • [33]Gallagher D, Visser M, De-Meersman RE, Sepulveda D, Baumgartner RN, Pierson RN, Harris T, Heymsfield SB: Appendicular skeletal muscle mass: Effects of age, gender, and ethnicity. J Appl Physiol 1997, 83:229-239.
  • [34]Pawelec G, Koch S, Franceschi C, Wikby A: Human immunosenescence: does it have an infectious component? Ann N Y Acad Sci 2006, 1067:56-65.
  • [35]Skipworth RJE, Stewart GD, Ross JA, Guttridge DC, Fearon KCH: The molecular mechanisms of skeletal muscle wasting: Implications for therapy. Surgeon 2006, 4:273-283.
  • [36]Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, Monden M: Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Investig 1996, 97:244-249.
  • [37]Weber MM, Michl P, Auernhammer CJ, Engelhardt D: Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells. Endocrinology 1997, 138:2207-2210.
  • [38]Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, Strain A, Hewison M, Stewart PM: Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: Tissue-specific induction by cytokines. Endocrinology 2001, 142:1982-1989.
  • [39]Janssen I, Heymsfield SB, Wang ZM, Ross R: Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. J Appl Physiol 2000, 89:81-88.
  • [40]Gallagher D, Heymsfield SB: Muscle distribution: variations with body weight, gender, and age. Appl Radiat Isot 1998, 49:733-734.
  • [41]Deary IJ, Gow AJ, Taylor MD, Corley J, Brett C, Wilson V, Campbell H, Whalley LJ, Visscher PM, Porteous DJ, Starr JM: The Lothian Birth Cohort 1936: A study to examine influences on cognitive ageing from age 11 to age 70 and beyond. BMC Geriatr 2007, 7:28. BioMed Central Full Text
  • [42]Deary IJ, Gow AJ, Pattie A, Starr JM: Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. Int J Epidemiol 2012, 41:1576-1584.
  • [43]Kilgour A, Subedi D, Gray C, Deary I, Lawrie S, Wardlaw J, Starr J: Design and validation of a novel method to measure cross-sectional area of neck muscles included during routine MR brain volume imaging. PLoS ONE 2012, 7:e34444.
  文献评价指标  
  下载次数:169次 浏览次数:170次